SPH 7485
Alternative Names: SPH-7485Latest Information Update: 16 Aug 2024
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 16 Aug 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT06487455)
- 17 Jul 2024 Preclinical trials in Solid tumours in China (PO) prior to July 2024
- 05 Jul 2024 Shanghai Pharmaceuticals Holding plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) (PO, Tablet) (NCT06487455)